RxDoctor Payments Data

Adam Dossey, MD

Ophthalmology · Tyler, TXNPI 1376546226

Payments from drug & device makers

$4,382in general payments, 2019–2025

Across 120 payments — averaging $36.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Alcon$531
  • NEW World Medical,inc.$502
  • Lensar, Inc.$243
  • Carl Zeiss Meditec USA, Inc.$217
  • Rxsight Inc$214
  • plus $881 from 15 others

What the payments were for

  • Speaking & faculty fees$261%
  • Food & beverage$4,14094%
  • Other$2175%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,382 in reported general payments places this provider in the 70th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$394,385
Medicare patients
704
Services billed
2,545

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost219$99,211
RestasisCyclosporine78$88,674
XiidraLifitegrast26$38,826
RhopressaNetarsudil Mesylate84$33,606
RocklatanNetarsudil Mesylat/Latanoprost65$28,606
VyzultaLatanoprostene Bunod55$24,621
SimbrinzaBrinzolamide/Brimonidine Tart88$21,218
Prednisolone Acetate242$16,884
Cyclosporine40$16,877
CombiganBrimonidine Tartrate/Timolol41$15,975
Brinzolamide70$13,010
Alphagan PBrimonidine Tartrate30$11,120
Latanoprost947$8,330
Dorzolamide Hcl252$4,988
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol45$4,660

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$1,793$214,980368 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$12$63,44681 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$24$62,213149 claims
AlconSimbrinza$531$21,21888 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate$17$7,86147 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Tyler

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →